Key clinical point : Adherence to current oral therapies for multiple sclerosis (MS) is poor.
Major finding : Almost half of patients with MS discontinue their initial oral therapy.
Study details : A retrospective administrative claims study of 8,251 patients with MS.
Disclosures: The authors received no financial support for this study. Dr. Nicholas reported receiving grant support from EMD Serono.
Citation: Nicholas J et al. CMSC 2019. Abstract DXT34.